Cleveland Clinic researchers analyzed chronic kidney disease progression and incident kidney failure data among 425 patients who either underwent metabolic surgery or continuously took GLP-1s for at least two years. All had Type 2 diabetes, obesity and stage 3 or 4 chronic kidney disease.
Compared to GLP-1s, metabolic surgery was associated with a 60% lower risk of kidney disease progression and a 44% lower risk of kidney failure or death.
“The study participants who underwent bariatric surgery experienced more weight loss and better control of their diabetes,” a Sept. 20 news release from Cleveland Clinic said. “They also required less medication to control their diabetes, high blood pressure and high cholesterol.”
The results were recently published in Annals of Surgery.
Another study, which did not compare GLP-1s to bariatric surgery, showed that Ozempic and Wegovy slowed the growth of chronic kidney disease and reduced the risk of heart attack, kidney failure, stroke and death. Read more here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
